Federal award (DEFINITIVE CONTRACT, fiscal year 2024)
Recipient: OREXO US INC
Awarding agency: Department of Health and Human Services / Office of Assistant Secretary for Preparedness and Response
Funding agency: Department of Health and Human Services / Office of Assistant Secretary for Preparedness and Response
Period of performance: 2025-09-24 to 2027-03-31
Current total value of award: $8450715
Description: CLINICAL DEVELOPMENT OF OX390 (ATIPAMEZOLE) AS AN ?2 AGONIST REVERSAL AGENT FOR HUMAN USE TO COUNTERACT THE SEDATIVE EFFECTS OF XYLAZINE, MEDETOMIDINE, AND OTHER ?2 AGONISTS